Fifty years of research (1968–2018) toward the identification of selective antiviral drugs have
been primarily focused on antiviral compounds active against DNA viruses (HSV, VZV, CMV …

The bicyclam AMD3100 (originally called JM3100), in which the two cyclam rings are
tethered by an aromatic bridge, emanated from JM2763, where the two cyclam moieties are …

The chemokine receptors CCR5 and CXCR4 function as coreceptors for human
immunodeficiency virus (HIV) and are attractive targets for the development of anti-HIV …

HIV cellular entry is a multistep process that requires the interaction of a viral envelope
glycoprotein (gp120) and a host receptor (CD4) followed by binding to a co-receptor. The …

The original bicyclam, JM1657 (JM standing for Johnson Matthey) was discovered as a
contaminant in a commercial preparation of monocyclams when evaluated for their anti-HIV …

Prominent in the current stage of antiviral drug development are:(i) for human
immunodeficiency virus (HIV), the use of fixed‐dose combinations (FDCs), the most recent …

Introduction: During embryogenesis, CXCR4, a chemokine receptor, and its ligand, stromal
cell-derived factor-1 (SDF-1/CXCL12), are critically involved in the development of the …

A polyphemusin peptide analogue, T22 ([Tyr5, 12, Lys7]-polyphemusin II), and its shortened
potent analogues, T134 (des-[Cys8, 13, Tyr9, 12]-[d-Lys10, Pro11, l-citrulline16]-T22 without …

CXCR4 and CCR5 constitute the two major coreceptors for HIV-1 entry into host cells. In the
course of an HIV-infection, a coreceptor switch takes place in approximately half of the …

Motivated by the pivotal role of CXCR4 as an HIV entry co-receptor, we herein report a de
novo hit-to-lead effort on the identification of subnanomolar purine-based CXCR4 …